ZA201507526B - Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type - Google Patents

Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Info

Publication number
ZA201507526B
ZA201507526B ZA2015/07526A ZA201507526A ZA201507526B ZA 201507526 B ZA201507526 B ZA 201507526B ZA 2015/07526 A ZA2015/07526 A ZA 2015/07526A ZA 201507526 A ZA201507526 A ZA 201507526A ZA 201507526 B ZA201507526 B ZA 201507526B
Authority
ZA
South Africa
Prior art keywords
immunotherapy
dementia
alzheimer
prevention
type
Prior art date
Application number
ZA2015/07526A
Other languages
English (en)
Inventor
Yi Wang Chang
Original Assignee
United Biomedical Inc A Corp Organised And Existing Under The Laws Of The State Of Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc A Corp Organised And Existing Under The Laws Of The State Of Delaware filed Critical United Biomedical Inc A Corp Organised And Existing Under The Laws Of The State Of Delaware
Publication of ZA201507526B publication Critical patent/ZA201507526B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA2015/07526A 2013-03-15 2015-10-09 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type ZA201507526B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/843,883 US9102752B2 (en) 2013-03-15 2013-03-15 Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
PCT/US2013/037865 WO2014143087A1 (en) 2013-03-15 2013-04-23 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Publications (1)

Publication Number Publication Date
ZA201507526B true ZA201507526B (en) 2019-12-18

Family

ID=51527985

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2015/07526A ZA201507526B (en) 2013-03-15 2015-10-09 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
ZA2019/06683A ZA201906683B (en) 2013-03-15 2019-10-10 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2019/06683A ZA201906683B (en) 2013-03-15 2019-10-10 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Country Status (18)

Country Link
US (4) US9102752B2 (enExample)
EP (1) EP2968485B1 (enExample)
JP (3) JP6208319B2 (enExample)
KR (2) KR101926030B1 (enExample)
CN (2) CN105228644B (enExample)
AU (3) AU2013381835A1 (enExample)
BR (1) BR112015023105A8 (enExample)
CA (1) CA2906313A1 (enExample)
DK (1) DK2968485T3 (enExample)
ES (1) ES2800028T3 (enExample)
IL (2) IL241597B (enExample)
MX (2) MX364689B (enExample)
PT (1) PT2968485T (enExample)
RU (1) RU2696566C2 (enExample)
SG (1) SG11201507669YA (enExample)
TW (1) TWI561529B (enExample)
WO (1) WO2014143087A1 (enExample)
ZA (2) ZA201507526B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
JP2017519810A (ja) * 2014-04-07 2017-07-20 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ ヘプシジン模倣ペプチドおよびその使用
KR101901669B1 (ko) 2016-01-27 2018-09-28 경상대학교산학협력단 아디포넥틴 수용체 활성화 신규 펩티드를 유효성분으로 포함하는 신경질환의 예방, 개선 또는 치료용 조성물
EP3444344A4 (en) * 2016-04-14 2020-02-19 TAO Health Life Pharma Co., Ltd. AMYLOSPHEROID (ASPD) -LIKE STRUCTURE AND PHARMACEUTICAL COMPOSITION
CN106565847B (zh) * 2016-10-26 2020-12-01 清华大学 化合物、多肽及其用途
AU2018283510B8 (en) * 2017-06-16 2025-09-18 United Neuroscience Peptide immunogens from the C-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
CA3079236A1 (en) * 2017-10-27 2019-05-02 United Neuroscience Tau peptide immunogen constructs
MX2020006105A (es) * 2017-12-11 2020-11-09 Ubi Ip Holdings Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
AU2017445171B2 (en) * 2017-12-31 2025-05-08 United Biomedical, Inc. Peptide immunogens and formulations thereof targeting membrane-bound IgE for treatment of IgE mediated allergic diseases
CA3091020A1 (en) * 2018-02-13 2019-08-22 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
TWI908707B (zh) 2018-04-10 2025-12-21 瑞士商Ａｃ免疫有限公司 抗Ａβ治療性疫苗
US20220023400A1 (en) * 2018-05-04 2022-01-27 Ubi Us Holdings, Llc. Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
TWI676635B (zh) * 2018-06-15 2019-11-11 英屬開曼群島商聯腦科學公司 α－突觸核蛋白Ｃ端胜肽免疫原及其用於治療突觸核蛋白疾病的配方
US20210347866A1 (en) * 2018-10-01 2021-11-11 United Neuroscience Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72
SG11202106485YA (en) * 2018-12-19 2021-07-29 United Biomedical Inc Artificial promiscuous t helper cell epitopes as immune stimulators for synthetic peptide immunogens
JP7569091B2 (ja) * 2018-12-28 2024-10-17 ユナイテッド・バイオメディカル・インコーポレーテッド インターロイキン６（ｉｌ－６）調節異常による影響を受ける疾患の免疫療法のための、ｉｌ－６を標的とするペプチド免疫原及びその製剤
JP7563765B2 (ja) * 2018-12-31 2024-10-08 ユナイテッド ニューロサイエンス リミテッド カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）を標的とするペプチド免疫原ならびに片頭痛の治療及び予防のためのそれらの配合物
CN110759987B (zh) * 2019-10-29 2021-06-08 中国人民解放军军事科学院军事医学研究院 构象特异性的重组Aβ1-42样寡聚体抗原、其制备方法和应用
CA3168991A1 (en) * 2020-01-23 2021-07-29 United Biomedical, Inc. Peptide immunogens targeting pituitary adenylate cyclase-activating peptide (pacap) and formulations thereof for prevention and treatment of migraine
WO2021180782A1 (en) 2020-03-10 2021-09-16 Lifearc Cyclic peptides
JP2023550052A (ja) 2020-11-17 2023-11-30 イリアド バイオテクノロジーズ，リミテッド ライアビリティ カンパニー 神経変性疾患に関連する神経病理の治療および予防
US20240159777A1 (en) * 2021-03-16 2024-05-16 Neurovision Imaging, Inc. Biofluid-Based Methods for Diagnosing Alzheimer’s Disease-Associated Conditions
WO2023034324A2 (en) * 2021-08-30 2023-03-09 The Brigham And Women’S Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2023106319A1 (ja) 2021-12-08 2023-06-15 国立大学法人大阪大学 抗ｉｌ－２３抗体誘導用ワクチン組成物
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
CN117586370A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN115417915B (zh) * 2022-11-03 2023-02-24 北京引正基因科技有限公司 多肽载体及其应用
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
WO1991016819A1 (en) 1990-04-27 1991-11-14 Molecular Rx., Inc. Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
WO1994017197A1 (fr) 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
AU7043894A (en) 1993-05-28 1994-12-20 Miriam Hospital, The Composition and method for (in vivo) imaging of amyloid deposits
WO1995011998A1 (en) 1993-10-26 1995-05-04 United Biomedical, Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6919075B1 (en) 1999-09-03 2005-07-19 Ramot At Tel Aviv University Ltd. Bacteriophage displaying aβ epitopes and method of use
CN1414976A (zh) 1999-12-08 2003-04-30 明德塞特生物制药(美国)公司 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
EP1711208A2 (en) * 2004-01-28 2006-10-18 Curix APS Conjugates of amyloid proteins as vaccines for amyloid-related diseases
KR20080103560A (ko) * 2006-02-22 2008-11-27 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신
CN101384279B (zh) * 2006-02-24 2012-02-22 奇斯药制品公司 抗淀粉样蛋白免疫原性组合物、方法和用途
US20090123488A1 (en) * 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
WO2010035261A2 (en) * 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
US9067981B1 (en) * 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2012056008A1 (en) * 2010-10-28 2012-05-03 Jonas Nilsson Diagnosis and treatment of alzheimer's disease
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type

Also Published As

Publication number Publication date
JP2017226646A (ja) 2017-12-28
JP2019196397A (ja) 2019-11-14
MX2015013235A (es) 2016-04-04
CN105228644A (zh) 2016-01-06
JP2016513638A (ja) 2016-05-16
US20190194280A1 (en) 2019-06-27
KR20180132962A (ko) 2018-12-12
AU2017203425A1 (en) 2017-06-08
PT2968485T (pt) 2020-06-26
US9102752B2 (en) 2015-08-11
EP2968485A1 (en) 2016-01-20
JP6784646B2 (ja) 2020-11-11
HK1212600A1 (zh) 2016-06-17
MX2019005268A (es) 2019-07-01
IL265910A (en) 2019-06-30
SG11201507669YA (en) 2015-10-29
US20180244739A1 (en) 2018-08-30
EP2968485B1 (en) 2020-03-04
MX364689B (es) 2019-05-06
US20160068581A1 (en) 2016-03-10
CN105228644B (zh) 2018-07-13
DK2968485T3 (da) 2020-06-08
EP2968485A4 (en) 2016-09-07
TW201434478A (zh) 2014-09-16
IL241597B (en) 2020-07-30
BR112015023105A2 (pt) 2017-11-21
US20140271690A1 (en) 2014-09-18
AU2019246916A1 (en) 2019-10-31
ZA201906683B (en) 2023-04-26
CN108794615A (zh) 2018-11-13
RU2019123453A (ru) 2019-09-10
JP6208319B2 (ja) 2017-10-04
AU2017203425B2 (en) 2019-07-11
TWI561529B (en) 2016-12-11
ES2800028T3 (es) 2020-12-23
BR112015023105A8 (pt) 2018-01-23
AU2013381835A1 (en) 2015-10-08
KR101926030B1 (ko) 2018-12-10
RU2015142996A (ru) 2017-04-24
CA2906313A1 (en) 2014-09-18
RU2696566C2 (ru) 2019-08-05
KR20150132396A (ko) 2015-11-25
WO2014143087A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
ZA201906683B (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
IL256296A (en) Particles of dimethyl fumarate and pharmaceutical preparations thereof
HUE052074T2 (hu) Mutáns VIII-as faktor készítmények és módszerek
ZA201901422B (en) Novel compounds and therapeutic uses thereof
IL248711A (en) Epixaben glycol esters as major intermediates and impurities in the process of epixaben synthesis
IL287985A (en) A peptide derived from koc1 and a component containing it
IL257335A (en) A depdc1-derived peptide and a component containing it
GB201423272D0 (en) The combination for anti-wrinkle and soothing the skin
LT3052513T (lt) Gamybinis procesas, skirtas ulipristalio acetato ir jo 4'-acetilo analogo sintezei
IL258700A (en) An excipient and a vaccine that includes it
IL251289A0 (en) New peptide derivatives and their use
EP3102590A4 (en) Antigenic epitopes from ebv gp350/220 and uses thereof
HUE047778T2 (hu) Dezmoglein 3 peptidek Pemphigus vulgarisban
IL250235A0 (en) A peptide derived from urlc10 and a component containing it
IL250215A0 (en) A peptide derived from cdca1 and a component containing it
IL251135A0 (en) A method for the synthesis of hydroxy-triglycerides and their use for the prevention and treatment of diseases
PL3226827T3 (pl) Niezawierające glinu kompozycje przeciwpotne/dezodorantowe i sposób ich wytwarzania
GB201421888D0 (en) Peptides derived from mysoin 19 and methods of use thereof
GB201615560D0 (en) Novel compounds and therapeutic uses thereof
GB201417777D0 (en) Novel compounds and therapeutic uses thereof
GB201402040D0 (en) Tie 'Not
GB201414038D0 (en) Alzheimer's disease
GB201401102D0 (en) Method and means of manufacturing 'inverted' augmented virtual siphon systems